Organon to Present VTAMA Cream Subgroup Analysis

A pooled post-hoc analysis of Phase 3 VTAMA data will be presented at the 2026 ACAAI Annual Scientific Meeting in Phoenix, Arizona.

Updated on Nov. 5, 2026 in Allergies

Organon to Present VTAMA Cream Subgroup Analysis

Organon will present a pooled post-hoc analysis of Phase 3 data for VTAMA cream at the 2026 ACAAI Annual Scientific Meeting in Phoenix, Arizona. The analysis evaluates efficacy across diverse patient subgroups based on baseline percent body surface area affected and other baseline characteristics.

Why it matters

The analysis examines how VTAMA cream performs across different patient groups with moderate to severe atopic dermatitis. VTAMA is the only aryl hydrocarbon receptor agonist indicated for both plaque psoriasis in adults and atopic dermatitis in adults and pediatric patients.

The ADORING program for atopic dermatitis comprised two 8-week pivotal trials and a 48-week open-label extension, and the presented analysis is pooled post-hoc Phase 3 data. Reported subgroup efficacy outcomes are not yet available in the source material.

The players

Organon

Organon is a global healthcare company headquartered in Jersey City, New Jersey, with a portfolio of over 70 products across Women's Health and General Medicines that is sold in more than 140 markets.

American College of Allergy, Asthma and Immunology (ACAAI)

The ACAAI is a professional medical society of allergists and immunologists that hosts an annual scientific meeting where clinical research is presented.

The details

Organon's analysis pools Phase 3 data for VTAMA cream, a 1% formulation, and looks at efficacy across subgroups defined by baseline characteristics. The most common adverse reactions in atopic dermatitis included upper respiratory tract infection, folliculitis, and headache, while plaque psoriasis reactions included folliculitis and nasopharyngitis.

• 2026: Organon presents the pooled VTAMA analysis at the ACAAI Annual Scientific Meeting in Phoenix, Arizona (specific date not provided).

Health Landscape

VTAMA's position as the only aryl hydrocarbon receptor agonist indicated for both psoriasis and atopic dermatitis places it among a narrow class of nonsteroidal topical options for skin disease. This subgroup analysis adds to the clinical evidence that will inform how such topical therapies are used across varied patient populations with atopic dermatitis.

For people with atopic dermatitis, the analysis may help clinicians understand how topical VTAMA cream performs across different disease severities and patient characteristics. Readers should discuss any treatment decisions with a dermatologist or allergist, since subgroup data does not itself change current prescribing guidance.

The takeaway

Subgroup analyses help show whether a treatment's benefit holds across the range of patients who actually receive it. Patients considering topical therapy for atopic dermatitis can ask their clinician how baseline disease extent affects expected results.